Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Soland, Melisa A ^a   Bego, Mariana ^b   Colletti, Evan ^c   Zanjani, Esmail D ^c   St Jeor, Stephen ^d   Porada, Christopher D ^a   Almeida Porada, Graça ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITY OF NEVADA   (United States)

^d UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR; HLA ANTIGEN CLASS 1; PROTEIN US11; PROTEIN US2; PROTEIN US3; PROTEIN US6; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL ASSAY; CELL ENGINEERING; CELL PROTECTION; CELL SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GENETIC TRANSFECTION; MESENCHYMAL STEM CELL; MOLECULAR RECOGNITION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

EID: 84875471300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060461     Document Type: Article

References (32)

1. Medzhitov R, Janeway CA Jr, (2002) Decoding the patterns of self and nonself by the innate immune system. Science 296: 298-300.
2. Wasowska BA, Lee C-Y, Halushka MK, Baldwin Iii WM, (2007) New concepts of complement in allorecognition and graft rejection. Cellular Immunology 248: 18-30.
3. Colvin RB, Smith RN, (2005) Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5: 807-817.
4. Sacks S, Zhou W, (2005) Allograft rejection: effect of local synthesis of complement. Springer Seminars in Immunopathology 27: 332-344.
5. Dunkelberger JR, Song WC, (2010) Complement and its role in innate and adaptive immune responses. Cell research 20: 34-50.
6. Sacks SH, Chowdhury P, Zhou W, (2003) Role of the complement system in rejection. Current Opinion in Immunology 15: 487-492.
7. Schraufstatter IU, Discipio RG, Zhao M, Khaldoyanidi SK, (2009) C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol 182: 3827-3836.
8. Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, et al. (2011) Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses. PLoS ONE 6: e21703.
9. Tu Z, Li Q, Bu H, Lin F, (2010) Mesenchymal Stem Cells Inhibit Complement Activation by Secreting Factor H. Stem Cells and Development 19. (11): 1803-1809.
10. Ignatius A, Schoengraf P, Kreja L, Liedert A, Recknagel S, et al. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β. Journal of Cellular Biochemistry 112: 2594-2605.
11. Li Y, Lin F, (2012) Mesenchymal stem cells are injured by complement after their contact with serum. Blood 120: 3436-3443.
12. Meyers JDFN, Thomas EDFN, (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153(3): 478-488.
13. Ploegh HL, (1998) Viral strategies of immune evasion. Science 280: 248-253.
14. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, et al. (1995) Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 155: 4376-4381.
15. Spiller OB, Morgan BP, Tufaro F, Devine DV, (1996) Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. European Journal of Immunology 26: 1532-1538.
16. Kim JY, Kim D, Choi I, Yang JS, Lee D-S, et al. (2005) MHC expression in a human adult stem cell line and its down-regulation by hCMV US gene transfection. The International Journal of Biochemistry & Cell Biology 37: 69-78.
17. Lee EM, Kim JY, Cho BR, Chung WK, Yoon B-W, et al. (2005) Down-regulation of MHC class I expression in human neuronal stem cells using viral stealth mechanism. Biochemical and Biophysical Research Communications 326: 825-835.
18. de la Garza-Rodea AS, Verweij MC, Boersma H, van der Velde-van Dijke I, de Vries AAF, et al. (2011) Exploitation of Herpesvirus Immune Evasion Strategies to Modify the Immunogenicity of Human Mesenchymal Stem Cell Transplants. PLoS ONE 6: e14493.
19. Soland MA, Bego MG, Colletti E, Porada CD, Zanjani ED, et al. (2012) Modulation of human mesenchymal stem cell immunogenicity through forced expression of human cytomegalovirus us proteins. PLoS ONE 7: e36163.
20. Colletti EJ, Airey JA, Liu W, Simmons PJ, Zanjani ED, et al. (2009) Generation of tissue-specific cells from MSC does not require fusion or donor-to-host mitochondrial/membrane transfer. Stem cell research 2: 125-138.
21. Díaz TM, Pértega S, Ortega D, López E, Centeno A, et al. (2004) FDA/PI flow cytometry assay of complement-mediated cytotoxicity of antibodies generated during xenotransplantation. Cytometry Part A 62A: 54-60.
22. Meri S, Morgan BP, Wing M, Jones J, Davies A, et al. (1990) Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis. The Journal of Experimental Medicine 172: 367-370.
23. Liszewski MK, Post TW, Atkinson JP, (1991) Membrane Cofactor Protein (MCP or CD46): Newest Member of the Regulators of Complement Activation Gene Cluster. Annual Review of Immunology 9: 431-455.
24. Nicholson-Weller A, Wang C, (1994) Structure and function of decay accelerating factor CD55. The Journal of laboratory and clinical medicine 123(4): 485-491.
25. Le Blanc K, (2006) Mesenchymal stromal cells: tissue repair and immune modulation. Cytotherapy 8: 559-561.
26. Porada CD, Almeida-Porada G, (2010) Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Advanced drug delivery reviews 62: 1156-1166.
27. Caplan AI, (2009) Why are MSCs therapeutic? New data: new insight. The Journal of Pathology 217: 318.
28. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EGA, Willemze R, et al. (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108: 2114-2120.
29. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J, (2005) Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106: 4057-4065.
30. Jiang H-Y, Wek SA, McGrath BC, Scheuner D, Kaufman RJ, et al. (2003) Phosphorylation of the alpha Subunit of Eukaryotic Initiation Factor 2 Is Required for Activation of NF-kB in Response to Diverse Cellular Stresses. Molecular and Cellular Biology 23: 5651-5663.
31. Cui W, Zhao Y, Shan C, Kong G, Hu N, et al. (2012) HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF-kB signaling to protect breast cancer cells from complement attack. FEBS Letters 586: 766-771.
32. Finberg RW, White W, Nicholson-Weller A, (1992) Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. The Journal of Immunology 149: 2055-2060.